SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2020 / Cilt: 4 - Sayı: 3

A Review on The Development, Production Strategies, and Utilization of Monoclonal Antibodies

Gamze SANLAV
Ömer BEKÇİOĞLU
Yasemin BAŞBINAR
Pages
197–204
Publication Date
2020-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Keywords: monoclonal antibodies, industry, cancer

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Over the last 20 years, monoclonal antibodies have become the backbone of biological therapeutics for the treatment and diagnosis of several diseases.
📊
Key Findings & Data:The rising incidence of cancer and other immunologic diseases promoted the increasing investments of the global pharmaceutical industry in monoclonal antibody development.
💡
Conclusion & Impact:Keywords: monoclonal antibodies, industry, cancer
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:monoclonal antibodies · industry · cancer

Abstract

Over the last 20 years, monoclonal antibodies have become the backbone of biological therapeutics for the treatment and diagnosis of several diseases. The rising incidence of cancer and other immunologic diseases promoted the increasing investments of the global pharmaceutical industry in monoclonal antibody development. The R&D has focused on the highest efficacy which is majorly correlated with the antigenbinding specificity and the lowest immunogenicity of monoclonal antibodies. This review aims to provide a brief description and explanation of each stage in the development path of mAbs. Keywords: monoclonal antibodies, industry, cancer

🔖

Cite This Article

SANLAV, G., BEKÇİOĞLU, Ö., BAŞBINAR, Y. (2020). A Review on The Development, Production Strategies, and Utilization of Monoclonal Antibodies. Journal of Basic and Clinical Health Sciences, Cilt: 4 - Sayı: 3, 197–204. https://ajindex.com/articles/163529

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Liu JKH. The history of monoclonal antibody development-Progress, remaining challenges and future innovations. Ann Med Surg 2014
  2. 113–116. [CrossRef] 2. Payne WJ, Marshall DL, Shockley RK, Martin WJ. Clinical laboratory applications of monoclonal antibodies. Clin Microbiol Rev 1988
  3. 313–329. [CrossRef 3. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs 2015
  4. 9–14. [CrossRef] 4. Walker N. Innovation at the Heart of Biopharmaceutical Industry Growth. Am Pharma Rev 2016. https://www. americanpharmaceuticalreview.com/Featured-Articles/187354- Innovation-at-the-Heart-of-Biopharmaceutical-Industry-Growth/ 5. Leavy O. The birth of monoclonal antibodies. Nat Immunol 2016
  5. S13. [CrossRef] 6. Levine HL, Cooney BR. The Development of Therapeutic Monoclonal Antibody Products. Needham, MA: Insight Pharma Reports
  6. p.1–10. 7. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 1986
  7. 730–733. [CrossRef] 8. Nicholson LB. The immune system. Essays Biochem 2016
  8. 275– 301. [CrossRef] 9. Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 2019
  9. [CrossRef] 10. Wang Q, Chen Y, Park J, et al. Design and Production of Bispecific Antibodies. Antibodies 2019
  10. [CrossRef] 11. Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy 2011
  11. 371–380. [CrossRef] 12. Baron D, Peters JH, Gieseler RKH, et al. Production of Hybridomas. In: Peters JH, Baumgarten H, editors. Monoclonal Antibodies. 1992. p.137–222. 13. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009
  12. 220–233. [CrossRef] 14. Lu RM, Hwang YC., Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020
  13. [CrossRef] 15. Yamashita M, Katakura Y, Shirahata S. Recent advances in the generation of human monoclonal antibody. Cytotechnology 2007
  14. 55–60. [CrossRef] 16. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs 2010
  15. 256–265. [CrossRef] 17. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005
  16. 69–83. [CrossRef] 18. Williams DG, Matt